Phosphodiesterase type 4 inhibitors for asthma: A real breakthrough or just expensive theophylline?

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 5, 2006, Pages 640-642

  Lipworth, Brian ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUTICASONE; MONTELUKAST; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; THEOPHYLLINE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATING ACTIVITY; CORTICOSTEROID THERAPY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

EID: 33646717639     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61060-5     Document Type: Editorial

References (13)

1. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 2003;167:813-818.
2. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005;365:167-175.
3. van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116:292-298.
4. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol. 2002;42:297-303.
5. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2005;96:677-684
6. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071-1076.
7. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, as an oral anti-inflammatory with beclomethasone dipropionate in asthma control. Allergy 2006;61:72-78.
8. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002;110:847-854.
9. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001;107:461-468.
10. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001;108:530-536.
11. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005;60:730-734.
12. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332-336.
13. Sont JK, Willems LN, Bel EH, et al; AMPUL Study Group. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med. 1999;159:1043-1051.